Description
ZINNAT® is an oral prodrug of cefuroxime, the bactericidal cephalosporin antibiotic, resistant to most beta-lactamases and active against a wide variety of gram-positive and gram-negative microorganisms. It is indicated for the treatment of infections caused by sensitive bacteria.
Susceptibility to ZINNAT® will vary with geography and time, and local susceptibility information should be consulted, where available (see Pharmacokinetics and Pharmacodynamics).
Indications include:
• Infections of the upper respiratory tract, for example, ear, nose and throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis.
• Lower respiratory tract infections, eg pneumonia, acute bronchitis, and acute exacerbations of chronic bronchitis.
• Genitourinary tract infections, for example pyelonephritis, cystitis and urethritis.
• Infections of the skin and soft tissues, for example :, furunculosis, pyoderma and impetigo.
• Gonorrhea, uncomplicated acute gonococcal urethritis, and cervicitis.
• Treatment of early-stage Lyme disease and subsequent prevention of late-stage Lyme disease.
Cefuroxime is also available as the sodium salt (ZINNAT® Solution for injection), for parenteral administration. This allows the use of sequential therapy with the same antibiotic in situations where a change from parenteral to oral therapy is clinically indicated.
In suitable situations, ZINNAT® is effective when used after initial therapy with ZINNAT® (cefuroxime sodium) solution for injection, in the treatment of pneumonia and acute exacerbations of chronic bronchitis.
Reviews
There are no reviews yet.